EFG Asset Management (Americas)’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-30,807
| Closed | -$2.54M | – | 124 |
|
|
2024
Q2 | $2.54M | Buy |
30,807
+10,991
| +55% | +$905K | 0.5% | 60 |
|
|
2024
Q1 | $1.73M | Sell |
19,816
-7,412
| -27% | -$647K | 0.53% | 52 |
|
|
2023
Q4 | $2.63M | Buy |
27,228
+432
| +2% | +$41.7K | 0.57% | 61 |
|
|
2023
Q3 | $2.37M | Buy |
26,796
+10,194
| +61% | +$902K | 0.57% | 54 |
|
|
2023
Q2 | $1.44M | Buy |
+16,602
| New | +$1.44M | 0.33% | 82 |
|
|
2021
Q1 | – | Sell |
-2,976
| Closed | -$261K | – | 139 |
|
|
2020
Q4 | $261K | Sell |
2,976
-60
| -2% | -$5.26K | 0.05% | 127 |
|
|
2020
Q3 | $231K | Sell |
3,036
-35,567
| -92% | -$2.71M | 0.05% | 128 |
|
|
2020
Q2 | $4.76M | Sell |
38,603
-10,367
| -21% | -$1.28M | 1.24% | 30 |
|
|
2020
Q1 | $4.14M | Sell |
48,970
-6,416
| -12% | -$542K | 1.33% | 24 |
|
|
2019
Q4 | $4.68M | Buy |
55,386
+21,222
| +62% | +$1.79M | 1.24% | 26 |
|
|
2019
Q3 | $2.3M | Sell |
34,164
-492
| -1% | -$33.2K | 0.69% | 60 |
|
|
2019
Q2 | $2.97M | Buy |
34,656
+535
| +2% | +$45.8K | 0.84% | 52 |
|
|
2019
Q1 | $3.03M | Sell |
34,121
-5,377
| -14% | -$478K | 0.92% | 49 |
|
|
2018
Q4 | $3.36M | Buy |
39,498
+4,019
| +11% | +$342K | 1.21% | 28 |
|
|
2018
Q3 | $3.44M | Buy |
35,479
+6,467
| +22% | +$627K | 0.99% | 37 |
|
|
2018
Q2 | $2.73M | Buy |
29,012
+17,340
| +149% | +$1.63M | 0.83% | 38 |
|
|
2018
Q1 | $946K | Buy |
11,672
+1,250
| +12% | +$101K | 0.39% | 59 |
|
|
2017
Q4 | $929K | Buy |
10,422
+3,069
| +42% | +$274K | 0.34% | 64 |
|
|
2017
Q3 | $684K | Buy |
7,353
+1,788
| +32% | +$166K | 0.26% | 71 |
|
|
2017
Q2 | $505K | Buy |
5,565
+1,976
| +55% | +$179K | 0.19% | 89 |
|
|
2017
Q1 | $315K | Buy |
+3,589
| New | +$315K | 0.12% | 99 |
|